Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INSR | P06213 | 1/20 | 0.65 |
| ▸ | IGF1R | P08069 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.49 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
| ▸ | QPCT | Q16769 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5365459 | 0.84 | INSR (0.47) | INSRIGF1RCYP2C19CNR2SLC6A2 | |
| SCHEMBL8017019 | 0.81 | INSR (0.54) | INSRIGF1RCYP2C19NR1H2NR1H3 | |
| SCHEMBL2960872 | 0.80 | CYP2C19 (0.78) | CYP2C19NR1H2NR1H3CNR2CRHBP | |
| SCHEMBL10974928 | 0.79 | CRHBP (0.68) | CYP2C19NR1H2NR1H3CNR2CRHBP | |
| SCHEMBL5268659 | 0.78 | ALOX5 (0.55) | INSRIGF1RCNR2TSHRALOX5 | |
| SCHEMBL7838397 | 0.78 | SLC6A2 (0.51) | INSRIGF1RCYP2C19CNR2TSHR | |
| SCHEMBL6305860 | 0.78 | CYP2C19 (0.45) | INSRIGF1RCYP2C19NR1H2NR1H3 | |
| SCHEMBL10507036 | 0.75 | CYP2C19 (0.46) | INSRIGF1RCYP2C19NR1H2NR1H3 | |
| SCHEMBL10368809 | 0.75 | SLC6A2 (0.59) | INSRIGF1RCYP2C19NR1H2NR1H3 | |
| SCHEMBL7841628 | 0.75 | SLC6A2 (0.60) | CYP2C19TSHRSLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120040723-A | Curable composition, cured film, organic EL element, and method for producing same | JSR株式会社 | 2025-05-27 | — | — | CN | disclosed |
| CN-118146493-A | Curable composition, cured film, organic EL element, method for producing the same, and compound | JSR株式会社 | 2024-06-07 | — | — | CN | disclosed |
| US-20050080090-A1 | Naphthalene derivatives | CHENARD BERTRAND L (US) | 2005-04-14 | — | — | US | disclosed |
| US-20020058811-A1 | Naphthalene derivatives | CHENARD BERTRAND L (US) | 2002-05-16 | — | — | US | disclosed |
| US-20010004669-A1 | Pyrazinyl-substituted naphthalene derivatives | CHENARD BERTRAND L (US) | 2001-06-21 | — | — | US | disclosed |
| EP-0689536-B1 | NAPHTHALENE DERIVATIVES | PFIZER (US) | 2001-05-23 | — | — | EP | disclosed |
| EP-0701819-B1 | Novel compositions containing sertraline and a 5-HT1D receptor agonist or antagonist | PFIZER (US) | 2000-08-16 | — | — | EP | disclosed |
| US-5597826-A | Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist | PFIZER INC. (US) | 1997-01-28 | — | — | US | disclosed |
| EP-0701819-A2 | Novel compositions containing sertraline and a 5-HT1D receptor agonist or antagonist | PFIZER INC. (US) | 1996-03-20 | — | — | EP | disclosed |
| EP-0689536-A1 | NAPHTHALENE DERIVATIVES | PFIZER INC. (US) | 1996-01-03 | — | — | EP | disclosed |
| WO-1994021619-A1 | NAPHTHALENE DERIVATIVES | PFIZER INC. (US) | 1994-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010004669-A1 | Pyrazinyl-substituted naphthalene derivatives | HTR4, HCRTR2, CNR2 | INSR 577/4885IGF1R 1619/4885CYP2C19 329/4885 |
| US-20050080090-A1 | Naphthalene derivatives | HTR4, NPY4R, HCRTR1 | INSR 292/4885IGF1R 621/4885CYP2C19 360/4885 |
| US-20020058811-A1 | Naphthalene derivatives | HTR4, CNR1, CNR2 | INSR 626/4885IGF1R 1230/4885CYP2C19 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.